phrykt

Aurinia Pharmaceuticals Inc. (AUPH): who owns it and who trades it

As of Nov 16, 2026, AUPH insiders reported 3 open-market sales worth $736K and 11 purchases worth $25.1M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Stephen P. Robertson (Chief Legal Officer), with $736K. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Aurinia Pharmaceuticals

From the latest filings

Overall: more buying than selling. Insiders and famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns AUPH

281 funds and institutions reported AUPH shares worth $1.3B at the end of Q2 2026, about 59% of the company. The largest holder is Tang Capital Management LLC with 9.8%.

Funds and institutions (13F) 59%Everyone else 41%

10 largest owners, by share of the company

Tang Capital Management LLC9.8%
BlackRock, Inc.6.2%
Goldman Sachs Group Inc4.2%
NEA Management Company, LLC3.0%
Two Sigma Investments, LP2.6%
Arrowstreet Capital, Limited Partnership2.5%
State Street Corp1.9%
Morgan Stanley1.7%
Marshall Wace, LLP1.5%
Geode Capital Management, LLC1.3%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Tang Capital Management LLC13.04M9.81%$221M+7%
BlackRock, Inc.8.19M6.16%$139M+4%
Goldman Sachs Group Inc5.62M4.23%$95.4M+292%
NEA Management Company, LLC3.97M2.99%$67.4MNo change
Two Sigma Investments, LP3.47M2.61%$58.8M+1%
Arrowstreet Capital, Limited Partnership3.26M2.45%$55.4M-1%
State Street Corp2.59M1.95%$43.9M+2%
Morgan Stanley2.31M1.74%$39.2M+3%
Marshall Wace, LLP2.04M1.54%$34.7M+9%
Geode Capital Management, LLC1.70M1.28%$28.9M+11%
Renaissance Technologies LLC1.55M1.16%$26.3M-7%
D. E. Shaw & Co., Inc.1.41M1.06%$23.9M-10%
Vanguard Portfolio Management LLC1.36M1.02%$23.1M+8%
Jacobs Levy Equity Management, Inc1.23M0.93%$20.9M+12%
Jupiter Asset Management Ltd1.09M0.82%$18.6M+36%
Lsv Asset Management1.08M0.81%$18.3M+4%
Nomura Holdings Inc978,6020.74%$16.6M+1%
AQR Capital Management LLC948,7510.71%$16.1MNo change
Northern Trust Corp863,5670.65%$14.7M+5%
Nuveen, LLC812,9150.61%$13.8M+24%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, AUPH insiders reported $25.1M of open-market purchases and $736K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$25.1M
11 trades, 1 people
Sales, 12 months
$736K
3 trades, 1 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Nov 13, 2026
Filed Nov 16, 2026

Purchases and sales by month

$8.4M$8.4MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 13, 2026Stephen P. RobertsonChief Legal OfficerSale11,867$15.97$190KForm 4
Sep 10, 2026Stephen P. RobertsonChief Legal OfficerSale11,939$15.95$190KForm 4
Aug 21, 2026Stephen P. RobertsonChief Legal OfficerSale20,975$16.97$356KForm 4
Jun 2, 2026Kevin Tang +1CEOPurchase206,005$15.28$3.1MForm 4
Jun 1, 2026Kevin Tang +1CEOPurchase343,521$15.28$5.2MForm 4
Jun 1, 2026Kevin Tang +1CEOPurchase99$15.34$1.5KForm 4
May 29, 2026Kevin Tang +1CEOPurchase2,299$15.35$35.3KForm 4
May 29, 2026Kevin Tang +1CEOPurchase262,682$15.31$4MForm 4
Mar 3, 2026Kevin TangDirectorPurchase184,208$14.22$2.6MForm 4
Mar 2, 2026Kevin TangDirectorPurchase83,561$14.33$1.2MForm 4
Mar 2, 2026Kevin TangDirectorPurchase115,792$14.21$1.6MForm 4
Feb 27, 2026Kevin TangDirectorPurchase214,839$14.12$3MForm 4
Feb 27, 2026Kevin TangDirectorPurchase1,600$14.38$23KForm 4
Feb 27, 2026Kevin TangDirectorPurchase300,000$13.90$4.2MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Kevin TangDirector$25.1M–Jun 2, 2026
Stephen P. RobertsonChief Legal Officer–$736KNov 13, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

AUPH short interest

Moderate short interest. 5.3% of AUPH shares are sold short: about 1 share in 19. Over the last 12 reports the number of shares short went down 21%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 7.14M AUPH shares were sold short, 5.3% of the shares outstanding, down 8.3% from the report before. At the average daily volume of 692,192 shares, buying them all back would take about 10.3 trading days (days to cover).

Shares short, % of all shares

5.33%May 15Oct 307.60%

Days to cover

10.3May 15Oct 3012.2

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20267.14M5.33%-8%692,19210.3
Oct 15, 20267.78M5.85%-2%868,4909.0
Sep 30, 20267.92M5.95%-8%844,5179.4
Sep 15, 20268.58M6.45%-4%774,11811.1
Aug 31, 20268.98M6.75%-7%1.05M8.6
Aug 14, 20269.62M7.23%+1%1.21M8.0
Jul 31, 20269.53M7.16%-2%1.01M9.4
Jul 15, 20269.71M7.31%+1%1.68M5.8
Jun 30, 20269.59M7.21%+4%2.47M3.9
Jun 15, 20269.25M6.96%+5%1.21M7.7
May 29, 20268.82M6.63%-2%1.12M7.9
May 15, 20269.02M6.79%+2%1.33M6.8

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Aurinia Pharmaceuticals company events

Aurinia Pharmaceuticals filed 9 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Oct 30, 2026.

  1. Oct 30, 2026ResultsReleased financial results. Filing
  2. Aug 19, 2026AnnouncementAurinia Pharmaceuticals Inc. (Aurinia or the Company) issued a press release announcing that it and its subsidiary, Aurinia Pharma U.S., Inc., (collectively, “Aurinia”) have entered into a settlement agreement with Teva Pharmaceuticals Inc. to resolve patent infringement litigation relating to… Filing
  3. Aug 6, 2026ResultsReleased financial results. Filing
  4. Jun 4, 2026VoteReported shareholder vote results. Filing
  5. May 11, 2026DealAs previously disclosed by Aurinia Pharmaceuticals Inc. in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 3, 2026, Aurinia Pharma U.S., Inc., a Delaware corporation, entered into an Agreement and Plan of Merger, dated as of March 30, 2026 by and among… Filing
  6. May 7, 2026ResultsReleased financial results. Filing
  7. Apr 3, 2026AgreementAurinia Pharma U.S., Inc., a Delaware corporation, entered into an Agreement and Plan of Merger by and among Kezar Life Sciences, Inc., a Delaware corporation, Parent, Aurinia Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent, and, solely for the purposes of Section… Filing
  8. Mar 23, 2026LeadershipDepartures of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
  9. Feb 26, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Aurinia Pharmaceuticals financials

Famous investors that hold AUPH

5 of the 50 well-known investors we track reported holding AUPH in their latest 13F filing. The largest position is Jim Simons's, worth $23.2M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 20261.43M$23.2M0.0%-7%
Ken Griffin · Citadel AdvisorsQ3 2026811,159$13.1M0.0%+237%
Steve Cohen · Point72 Asset ManagementQ3 2026223,907$3.6M0.0%New
Paul Tudor Jones · Tudor Investment CorpQ3 202647,854$775K0.0%New
Israel Englander · Millennium ManagementQ3 202616,895$274K0.0%-93%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Aurinia Pharmaceuticals Inc. (AUPH) stock

Who owns the most AUPH stock?

The largest reported owner of Aurinia Pharmaceuticals Inc. (AUPH) is Tang Capital Management LLC, with 9.8% of the company. In total, 281 funds and institutions reported holding AUPH at the end of Q2 2026, together about 59% of the shares. See the largest owners.

Are AUPH insiders buying or selling?

In the last 12 months, AUPH insiders reported 11 open-market purchases worth $25.1M and 3 sales worth $736K. The latest trade was on Nov 13, 2026. See every trade.

What is the short interest in AUPH?

As of Oct 30, 2026, 7.14M AUPH shares were sold short, 5.3% of the shares outstanding, down 8.3% from the report before. At the average daily volume of 692,192 shares, buying them all back would take about 10.3 trading days (days to cover). See the history.

Which famous investors hold AUPH?

5 of the 50 well-known investors we track reported AUPH in their latest 13F filing, including Jim Simons, Ken Griffin, Steve Cohen. The largest position is worth $23.2M. See all holders.

Executive pay

Aurinia Pharmaceuticals's chief executive was paid a total of $5.9M for the year ended Dec 31, 2025, down 9% from $6.4M the year before. In the last 12 months, Aurinia Pharmaceuticals's executives and directors bought $25.1M of stock on the open market and sold $736K.

Chief executive, total pay$5.9MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$17.6MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$2.1MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.